Importantly, recent studies suggest that it is possible to develop PPARγ ligands that dissociate one cell-specific PPARγ function from another (185), offering the possibility of being able to identify a new PPARγ agonist ligand that will ameliorate IBD but not exert cardiotoxicity. Here, PPARG is linked to inflammatory bowel disease.